A phase I/II study of vaccination against minor histocompatibility antigens HA1 or HA2 after allogeneic stem cell transplantation for advanced haematological malignancies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11974092

Enrollment

Registered

2008-11-20

Start date

2008-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological malignacies/leukaemic relapse Cancer Leukaemia of unspecified cell type

Interventions

All patients will receive immunisation with mHA1 or 2 peptides in HLA-A2 patients with donor-recipient disparities in mHA1 or 2. Historical controls will be used for evaluation of a benefit for patie

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Advanced (high risk) leukaemia, after allogeneic haematopoietic stem cell transplantation (HSCT) 2. Disparity in HA1 or HA2 between donor and recipient 3. Informed consent 4. Aged 18 years or older, either sex

Exclusion criteria

Exclusion criteria: 1. Acute or chronic graft-versus-host disease (GvHD) after allo-HSCT prior to immunisation 2. No informed consent

Design outcomes

Primary

Measure	Time frame
Toxicity of immunisation	—

Secondary

Measure	Time frame
Prevention of relapse of leukaemia	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026